Expression and Methylation Status of , , and Genes in Colon Adenocarcinoma Cell Lines: Promising Treatment Targets

Overview

Journal Gastroenterol Hepatol Bed Bench

Specialty Gastroenterology

Date 2023 Feb 10

PMID 36762213

Authors

Mehran Erfani

Mozhdeh Zamani

Gholamhossein Tamaddon

Seyed Vahid Hosseini

Pooneh Mokarram

Affiliations

Soon will be listed here.

Abstract

Aim: This study investigated the association between methylation status and expression levels of , , and genes in colon cancer.

Background: Aberrant DNA methylation is one of the most important epigenetic modifications in the development of cancer. Evidence indicates that hypermethylation of various tumor suppressor genes could be a potential mechanism of colon tumorigenesis.

Methods: The expression levels of , , and genes were evaluated in HT-29/219, HCT116, SW48, SW742, SW480, and LS180 cell lines using quantitative Real-Time PCR. The methylation status of and was determined by methylation-specific PCR (MSP) method, and the methylation pattern of PEG3 was evaluated by bisulfite sequencing PCR (BSP). To investigate the effect of methylation on the expression of these genes, all colon cancer cell lines were treated by 5-Azacitidine (5-Aza) and/or Trichostatin A (TSA).

Results: The expression levels of , , and were highly heterogeneous and quantitatively correlated to their promoter methylation status in the studied colon cancer cell lines. Treatment by 5-Aza and/or TSA increased the expression of the above-named genes in colon cancer cell lines.

Conclusion: Overall, it seems that , , and act as tumor suppressor genes in colon cancer, and methylation is a potential mechanism for their loss of expression. Therefore, these genes may be considered as suitable targets for demethylation approaches and, eventually, colon cancer treatment. Combined treatment by 5-Aza and TSA may be a promising therapeutic strategy for colon cancer treatment. Further studies may contribute to confirm these results.

Citing Articles

CircGPRC5A enhances colorectal cancer progress by stabilizing PPP1CA and inducing YAP dephosphorylation.

Chen Z, Li Y, He K, Yang J, Deng Q, Chen Y J Exp Clin Cancer Res. 2023; 42(1):334.

PMID: 38057879 PMC: 10698990. DOI: 10.1186/s13046-023-02915-7.

References

Maegawa S, Yoshioka H, Itaba N, Kubota N, Nishihara S, Shirayoshi Y . Epigenetic silencing of PEG3 gene expression in human glioma cell lines. Mol Carcinog. 2001; 31(1):1-9. DOI: 10.1002/mc.1034. View

Feng W, Marquez R, Lu Z, Liu J, Lu K, Issa J . Imprinted tumor suppressor genes ARHI and PEG3 are the most frequently down-regulated in human ovarian cancers by loss of heterozygosity and promoter methylation. Cancer. 2008; 112(7):1489-502. DOI: 10.1002/cncr.23323. View

Wise I, Charchar F . Epigenetic Modifications in Essential Hypertension. Int J Mol Sci. 2016; 17(4):451. PMC: 4848907. DOI: 10.3390/ijms17040451. View

Zhang Y, Wei L, Liu M, Li J, Zheng Y, Gao Y . BTG2 inhibits the proliferation, invasion, and apoptosis of MDA-MB-231 triple-negative breast cancer cells. Tumour Biol. 2013; 34(3):1605-13. DOI: 10.1007/s13277-013-0691-5. View

Zamani M, Hosseini S, Mokarram P . Epigenetic biomarkers in colorectal cancer: premises and prospects. Biomarkers. 2016; 23(2):105-114. DOI: 10.1080/1354750X.2016.1252961. View

Li B, Liu X, Wu G, Liu J, Cai S, Wang F . MicroRNA-934 facilitates cell proliferation, migration, invasion and angiogenesis in colorectal cancer by targeting B-cell translocation gene 2. Bioengineered. 2021; 12(2):9507-9519. PMC: 8809948. DOI: 10.1080/21655979.2021.1996505. View

Struckmann K, Schraml P, Simon R, Elmenhorst K, Mirlacher M, Kononen J . Impaired expression of the cell cycle regulator BTG2 is common in clear cell renal cell carcinoma. Cancer Res. 2004; 64(5):1632-8. DOI: 10.1158/0008-5472.can-03-1687. View

Zhang L, Huang H, Wu K, Wang M, Wu B . Impact of BTG2 expression on proliferation and invasion of gastric cancer cells in vitro. Mol Biol Rep. 2009; 37(6):2579-86. DOI: 10.1007/s11033-009-9777-y. View

Ordovas J, Smith C . Epigenetics and cardiovascular disease. Nat Rev Cardiol. 2010; 7(9):510-9. PMC: 3075976. DOI: 10.1038/nrcardio.2010.104. View

10.

Li J, Sun C, Cai W, Li J, Rosen B, Chen J . Insights into S-adenosyl-l-methionine (SAM)-dependent methyltransferase related diseases and genetic polymorphisms. Mutat Res Rev Mutat Res. 2021; 788:108396. PMC: 8847900. DOI: 10.1016/j.mrrev.2021.108396. View

11.

Baylin S, Jones P . Epigenetic Determinants of Cancer. Cold Spring Harb Perspect Biol. 2016; 8(9). PMC: 5008069. DOI: 10.1101/cshperspect.a019505. View

12.

Shen S, Zhang R, Guo Y, Loehrer E, Wei Y, Zhu Y . A multi-omic study reveals BTG2 as a reliable prognostic marker for early-stage non-small cell lung cancer. Mol Oncol. 2018; 12(6):913-924. PMC: 5983115. DOI: 10.1002/1878-0261.12204. View

13.

Mokarram P, Zamani M, Kavousipour S, Naghibalhossaini F, Irajie C, Moradi Sarabi M . Different patterns of DNA methylation of the two distinct O6-methylguanine-DNA methyltransferase (O6-MGMT) promoter regions in colorectal cancer. Mol Biol Rep. 2012; 40(5):3851-7. DOI: 10.1007/s11033-012-2465-3. View

14.

Yang C, Yue J, Pfeffer S, Handorf C, Pfeffer L . MicroRNA miR-21 regulates the metastatic behavior of B16 melanoma cells. J Biol Chem. 2011; 286(45):39172-8. PMC: 3234742. DOI: 10.1074/jbc.M111.285098. View

15.

Aggen J, Nairn A, CHAMBERLIN R . Regulation of protein phosphatase-1. Chem Biol. 2000; 7(1):R13-23. DOI: 10.1016/s1074-5521(00)00069-7. View

16.

Abdolmaleky H, Thiagalingam S, Wilcox M . Genetics and epigenetics in major psychiatric disorders: dilemmas, achievements, applications, and future scope. Am J Pharmacogenomics. 2005; 5(3):149-60. DOI: 10.2165/00129785-200505030-00002. View

17.

Chen M, Liao W, Lu Z, Bornmann W, Hennessey V, Washington M . Decitabine and suberoylanilide hydroxamic acid (SAHA) inhibit growth of ovarian cancer cell lines and xenografts while inducing expression of imprinted tumor suppressor genes, apoptosis, G2/M arrest, and autophagy. Cancer. 2011; 117(19):4424-38. PMC: 3137708. DOI: 10.1002/cncr.26073. View

18.

Erfani M, Hosseini S, Mokhtari M, Zamani M, Tahmasebi K, Alizadeh Naini M . Altered ARID1A expression in colorectal cancer. BMC Cancer. 2020; 20(1):350. PMC: 7183124. DOI: 10.1186/s12885-020-6706-x. View

19.

Castro M, Ferrer I, Cascon A, Guijarro M, Lleonart M, Cajal S . PPP1CA contributes to the senescence program induced by oncogenic Ras. Carcinogenesis. 2008; 29(3):491-9. DOI: 10.1093/carcin/bgm246. View

20.

Mattiuzzi C, Sanchis-Gomar F, Lippi G . Concise update on colorectal cancer epidemiology. Ann Transl Med. 2020; 7(21):609. PMC: 7011596. DOI: 10.21037/atm.2019.07.91. View